Trends in oral anticoagulant prescription in patients with nonvalvular atrial fibrillation in Flanders and the impact of switching patients from vitamin K antagonists to DOACS in terms of the burden caused by complications of the disease: a registry-based study.
Elvire NakhoulBert VaesPavlos MamourisJean-Marie DegrysePublished in: Acta clinica Belgica (2022)
In this registry-based study, we found a significant positive trend in OAC use in Flanders between 2002 and 2019. Switching to DOACs seems cost-effective compared to a threshold of 20000€/DALY.
Keyphrases
- atrial fibrillation
- direct oral anticoagulants
- end stage renal disease
- venous thromboembolism
- oral anticoagulants
- ejection fraction
- newly diagnosed
- left atrial appendage
- chronic kidney disease
- heart failure
- left atrial
- peritoneal dialysis
- catheter ablation
- risk factors
- coronary artery disease
- acute coronary syndrome